| abstract |
(57) [Summary]nThe present invention has a higher affinity for rat prostate estrogen receptor samples than for rat uterine estrogen receptor samples in vitro, and advantageously has a selective effect on bone in vivo compared to uterus and / or 5HT2a. A novel compound as a pharmaceutical agent having an excellent effect on the stimulation of the expression of -receptors and -transporters, its preparation, its therapeutic application and pharmaceutical dosage forms containing this novel compound are described. The new compounds are 16α- and 16β-hydroxy-estra-1,3,5 (10) -trienes, which have other substituents on the steroid skeleton and have a ring B, ring C and / or It can have one or more additional double bonds in the D ring. |